A compound of the formula Cy is aryl, heteroaryl or heterocycle, each is substituted by R 1 and optionally substituted by halogen, halo C 1-4 alkyl, C 1-4 alkyl and C 1-4 alkoxy; R 1 is chosen from: L-Ar, C 1-6 alkyl, -S m -R 3 and C 1-6 alkoxy, each Ar, C 1-6 alkyl and C 1-6 alkoxy are optionally substituted by halogen, halo C 1-4 alkyl, C 1-4 alkyl, R 2 -S m -, -CN, -C -N(R 3) 2 or C 1-4 alkoxy; L is a linker chosen from a bond, O, >C, -(CH 2) n -, -O-(CH 2) n -, -N(R 3)-, -N(R 3)-(CH 2) n -, -(CH 2) n -N(R 3)-, -C -N(R 3)-, -C -N(R 3)-(CH 2) n -,-N(R 3)-C -N(R 3)-, -N(R 3)-C -, -S m -N(R 3)-, and -N(R 3)-S m -, wherein the -CH 2 - in each L can have 1-2 hydrogens replaced by C 1-3 alkyl, said C 1-3 alkyl groups can optionally cyclize to form a C 3-6 cycloalkyl ring; Ar is carbocycle, heterocycyl or heteroaryl; Ring A of the formula is an N-linked heterocycle chosen from C 5 -C 10 spirocycle and a nitrogen containing optionally bridged mono- or bi-cyclic heterocycle, each Ring A is substituted by one Y and optionally substituted by halogen, halo C 1-4 alkyl, C 1-4 alkyl and C 1-4 alkoxy; Y is -(CH 2) n -N(R 3)-R 4, or Y is R 4; R 4 is wherein R 5 cannot be hydrogen, each n is independently 1-4; each m is independently 0-2; each R 2 and R 3 are independently chosen from hydrogen or C 1-4 alkyl; each R 5 is independently chosen from hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylC 1-4 alkoxy, C 1-4 alkylhydroxy, -(CH 2) n -heterocycle and heterocycle each heterocycle optionally substituted by halogen, OH or R 2 -S m -; each group defined above for Cy, R 1 -R 5, and Y can be where possible partially or fully halogenated; or a pharmaceutically acceptable salt or hydrates thereof. L-Ar, C 1-6 alkyl, -S m -R 3 and C 1-6 alkoxy, each Ar, C 1-6 alkyl and C 1-6 alkoxy are optionally substituted by halogen, halo C 1-4 alkyl, C 1-4 alkyl, R 2 -S m -, -CN, -C -N(R 3) 2 or C 1-4 alkoxy; L is a linker chosen from a bond, O, >C, -(CH 2) n -, -O-(CH 2) n -, -N(R 3)-, -N(R 3)-(CH 2) n -, -(CH 2) n -N(R 3)-, -C -N(R 3)-, -C -N(R 3)-(CH 2) n -,-N(R 3)-C -N(R 3)-, -N(R 3)-C -, -S m -N(R 3)-, and -N(R 3)-S m -, wherein the -CH 2 - in each L can have 1-2 hydrogens replaced by C 1-3 alkyl, said C 1-3 alkyl groups can optionally cyclize to form a C 3-6 cycloalkyl ring; Ar is carbocycle, heterocycyl or heteroaryl; Ring A of the formula is an N-linked heterocycle chosen from C 5 -C 10 spirocycle and a nitrogen containing optionally bridged mono- or bi-cyclic heterocycle, each Ring A is substituted by one Y and optionally substituted by halogen, halo C 1-4 alkyl, C 1-4 alkyl and C 1-4 alkoxy; Y is -(CH 2) n -N(R 3)-R 4, or Y is R 4; R 4 is wherein R 5 cannot be hydrogen, each n is independently 1-4; each m is independently 0-2; each R 2 and R 3 are independently chosen from hydrogen or C 1-4 alkyl; each R 5 is independently chosen from hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylC 1-4 alkoxy, C 1-4 alkylhydroxy, -(CH 2) n -heterocycle and heterocycle each heterocycle optionally substituted by halogen, OH or R 2 -S m -; each group defined above for Cy, R 1 -R 5, and Y can be where possible partially or fully halogenated; or a pharmaceutically acceptable salt or hydrates thereof. each n is independently 1-4; each m is independently 0-2; each R 2 and R 3 are independently chosen from hydrogen or C 1-4 alkyl; each R 5 is independently chosen from hydrogen, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylC 1-4 alkoxy, C 1-4 alkylhydroxy, -(CH 2) n -heterocycle and heterocycle each heterocycle optionally substituted by halogen, OH or R 2 -S m -; each group defined above for Cy, R 1 -R 5, and Y can be where possible partially or fully halogenated;